- Generating novel antibodies targeting AML-associated antigen and developing therapeutics based on these antibodies
- Developing of innovative strategies to overcome the limitations of bispecific antibodies and improve AML immunotherapy
- Developing genome editing-based genomic approach to improve safety of AML therapies
- Overcoming checkpoint inhibition as an approach to combinatorial therapy for AML
- Developing rational strategies to improve AML therapy with gemtuzumab ozogamicin and other antibody-drug conjugates
- Developing new approaches to radioimmunotherapy of AML
- Improving adoptive cell therapy for AML with chimeric antigen receptor (CAR)-modified immune effector cells
- Exploring the value of natural killer (NK)-cell based immunotherapy for AML
- Using genome-scale CRISPR/Cas9 knockout screes to develop rational combination therapies that overcome AML cell resistance to antibody-based therapeutics